Researchers at the American Academy of Ophthalmology meeting found NAION patients on GLP-1 drugs tended to develop it in the other eye sooner.
Recap by typeshit. Full story at Medical Xpress.
Both suppliers of compounded semaglutide and tirzepatide ingredients landed on the FDA import-alert list. Times Now also covers dosing mistakes with compounded vials.
Penn researchers stress the self-reports in JAMA Network Open don't prove the drug caused anything, but increased appetite topped the list despite trials pointing to nausea.
The visits came in the country's largest healthcare system, with the trend credited to wellness influencers and young people among those affected.
MedPage Today
A mental health news roundup points to a New York Times report that patients with eating disorders have little protection as GLP-1 use grows.
A link to a betting market on whether Lilly's retatrutide gets FDA approval, with no reporting or detail on the drug's actual status.
The GLP-1 Bridge pilot runs through 2027 and covers approved pills and shots for eligible Part D and Advantage enrollees, with no deductible.
Loading…